NIFTY  9,616.80  0.23%
  SENSEX  31,102.40  0.24%
 CURRENCY  Rs  64.45/$ 72.07/€, 82.52/£
  GOLD  28,884.00  0.78%
  SILVER  40,130.00  0.82%
  DAX  12,602.20  -0.15%
  FTSE  7,547.63  0.40%
  CAC  5,336.64  -0.01%
  HANG SENG  25,639.30  0.03%
  NIKKEI  19,686.80  -0.64%
  Shanghai Composite  3,110.06  0.04%
  DOW JONES  21,080.30  -0.01%
  NASDAQ  6,210.19  0.08%
  S&P 500  2,415.82  0.03%
MANISHI RAYCHAUDHURI : Feeling Slightly Circumspect About The Indian Markets MANISHI RAYCHAUDHURI : May See Some Earnings Upside In H2FY18 MANISHI RAYCHAUDHURI : Many Investors Will Find A Better Buying Opportunity Post Some Correction MANISHI RAYCHAUDHURI : Avoiding Pharma Sector In The Model Portfolio For The Last 1 Year MANISHI RAYCHAUDHURI : Have Cut Down Exposure Towards Indian I.T. By 50% MANISHI RAYCHAUDHURI : Indian I.T. Companies Need To Make Some Structural Changes To Better Margins

Ranbaxy Mohali Plant Worries Continue


Play this video

September 17: Ranbaxy has come under the USFDA spotlight yet again for all the wrong reasons. After a record $500 million settlement, the worries for the Mohali plant now take centre stage. Ranbaxy has just issued a statement saying steps will be taken to resolve FDA concerns. Bloomberg TV India tells you that a third-party inspection of the Mohali plant will be likely and what the company needs to do to salvage the situation.